Clinical Utility of 18F-Fluciclovine PET / MRI Imaging following Focal Cryo-Ablation of Prostate Cancer
This trial studies 18F-fluciclovine positron emission tomography (PET) / magnetic resonance imaging (MRI) in identifying the recurrence of prostate cancer in men who have undergone focal cryoablation. PET imaging uses a radioactive drug (tracer) to make images of tissues in the body and how they are functioning. The PET tracer used in this study, 18F-fluciclovine, binds or sticks more to prostate cancer cells than surrounding normal tissues, which can be seen on the images. MRI uses radio waves and a magnet to make pictures of areas inside the body. The purpose of this study is to see if PET imaging with 18F-fluciclovine helps to identify recurrence of prostate cancer.
- FCA at New York University (NYU) Langone Health performed at least two years prior to study enrollment by Drs. Lepor or Wysock.
- No prostate cancer specific treatment following FCA.
- Consented to undergo reflex MRI and prostate biopsy two years following FCA.
- Any contraindication to prostate biopsy.
- Prior allergic reaction to 18F-fluciclovine.
- Patient refuses MRI and prostate biopsy two years following FCA.
Locations & Contacts
Contact: Herbert Lepor
Trial Objectives and Outline
I. To evaluate if PET imaging with fluciclovine F18 (18F-fluciclovine) (Axumin) improves sensitivity for detecting significant in field prostate cancer following focal cryoablation (FCA).
I. To determine if PET imaging with 18F-fluciclovine (Axumin) improves sensitivity and negative predictive value for detecting significant out of field disease recurrence following FCA.
Patients receive fluciclovine F18 intravenously (IV) and undergo PET imaging over 20-30 minutes and MRI over 40 minutes.
Trial Phase & Type
No phase specified
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Secondary IDs NCI-2019-04329
Clinicaltrials.gov ID NCT04009083